Mounjaro, a GLP-1 receptor agonist, works by slowing digestion and suppressing appetite, leading to reduced caloric intake ...

Mounjaro, a weekly injection, targets GIP and GLP-1 hormones to enhance insulin release and appetite regulation, aiding ...

US -based pharmaceutical giant Eli Lilly recently launched its weight loss drug Mounjaro in India. Tirzepatide is the generic ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

Popular anti-diabetes and obesity drug Mounjaro, containing the active ingredient tirzepatide, is now available in India in a ...

Mounjaro (Tirzepatide), a groundbreaking GLP-1 receptor agonist targeting GIP receptors, is now available in India for ...

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...